ANDA 212334, held by Cipla. Dihydroergotamine Mesylate.
As of Nov 15, 2026, ANDA 212334 (Dihydroergotamine Mesylate), held by Cipla, was first approved by FDA on Sep 20, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 20, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dihydroergotamine Mesylate1MG/ML ยท injectable;injection | Dihydroergotamine Mesylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
